Drug Interactions With Risk of QT-prolongation in a General Hospital

NCT02043912 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 222

Last updated 2014-06-11

No results posted yet for this study

Summary

In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation. Additional clinical risk factors for developing QT-prolongation and safety measurements will be documented.

Conditions

Interventions

DRUG

Haloperidol

Sponsors & Collaborators

  • Agentschap voor Innovatie door Wetenschap en Technologie

    collaborator OTHER
  • KU Leuven

    lead OTHER

Principal Investigators

  • Eline Vandael, PhD-student · KU Leuven

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-02-28
Completion
2014-04-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02043912 on ClinicalTrials.gov